{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:17:17Z","timestamp":1788182237258,"version":"build-2803163510"},"reference-count":53,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of relacorilant (Lifyorli) in combination with nab-paclitaxel (NP) for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy, including at least one bevacizumab-containing regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted using Embase and PubMed\/MEDLINE, applicable published abstracts, and ongoing studies from ClinicalTrials.gov between January 1, 1981, and July 1, 2026. Keywords included relacorilant, Lifyorli, and CORT125134.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All English-language studies involving relacorilant for the treatment of cancer or other conditions were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Relacorilant is a highly selective, nonsteroidal, reversible glucocorticoid receptor antagonist approved in combination with NP based primarily on a phase 3 clinical trial of 381 patients, in which relacorilant plus NP significantly improved progression-free and overall survival compared with NP alone. Serious adverse events (AEs) occurred in 35% of patients receiving the combination, although treatment discontinuation due to AEs was uncommon. Common AEs associated with the combination included neutropenia, anemia, thrombocytopenia, nausea, and fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:<\/jats:title>\n                    <jats:p>Platinum-resistant ovarian cancer remains a difficult-to-treat disease with limited therapeutic options. Unlike biomarker-restricted therapies, relacorilant plus NP improved survival outcomes in a heavily pretreated, biomarker-independent population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Relacorilant represents a novel strategy for reversing chemoresistance in combination with NP alongside a manageable safety profile for heavily pretreated patients with platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261477395","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:30:41Z","timestamp":1787898641000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Relacorilant in Combination With Nab-Paclitaxel for the Treatment of Adults With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"],"prefix":"10.1177","author":[{"given":"Emilie J.","family":"Lynch","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Florida Health Shands Hospital, Gainesville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren T.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4738-7392","authenticated-orcid":false,"given":"Kelli N.","family":"Corona","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebola O.","family":"Fatimilehin","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-3792","authenticated-orcid":false,"given":"Nathan D.","family":"Seligson","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Jacksonville, USA"},{"name":"Precision Medicine, Nemours Children\u2019s Health, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.9495"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01771"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0197"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5607"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3877"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.04.012"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.06.033"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071649"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2131"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0182"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0296"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03009-4"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02630-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqag019"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-4426"},{"key":"e_1_3_2_19_2","unstructured":"US Food and Drug Administration. FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancer. Accessed July 7 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00462-9"},{"key":"e_1_3_2_21_2","article-title":"Relacorilant (Lifyorli) [package insert]","author":"Corcept Therapeutics Inc","year":"2026","unstructured":"Corcept Therapeutics Inc. Relacorilant (Lifyorli) [package insert]. Corcept Therapeutics Inc; 2026.","journal-title":"Corcept Therapeutics Inc;"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091286"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.07.003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jMed.chem.7b00162"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnae008"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010842200"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27989"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.08.005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-026-02230-x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27349-7"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.389"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02624"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.09.011"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4363"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01040-2"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/Oncol.o\/oyae210"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3636"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00362-6"},{"key":"e_1_3_2_39_2","unstructured":"Reuters. Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer. Accessed July 7 2026. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/corcept-therapeutics-shares-surge-lead-drug-gets-fda-nod-ovarian-cancer-2026-03-25\/"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e63"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e139"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e140"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-026-02109-7"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06277-9"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.11.010"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaOncol.2025.5763"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00602-1"},{"key":"e_1_3_2_50_2","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (Version 4.2026). Accessed July 7 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"key":"e_1_3_2_51_2","unstructured":"SGO. SGO statement: carboplatin and cisplatin shortages. Accessed July 7 2026. https:\/\/www.sgo.org\/news\/drugshortage\/"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33150-2"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad083"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110312"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261477395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261477395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261477395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:26:11Z","timestamp":1788179171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261477395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":53,"alternative-id":["10.1177\/10600280261477395"],"URL":"https:\/\/doi.org\/10.1177\/10600280261477395","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"10600280261477395"}}